Evelyn Partners Investment Management (Europe)’s AstraZeneca AZN Stock Holding History

Evelyn Partners Investment Management (Europe)’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.27M	Buy	+21,991	New	+$4.24M	1.47%	19

Other funds holding AZN

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $148B AUM

Evelyn Partners Investment Management (Europe)'s AZN Position: Q1 2026 in Review

Evelyn Partners Investment Management (Europe) opened a new position in AstraZeneca (AZN) in Q1 2026: 21,991 shares worth $4.27M. The stake represents 1.47% of the portfolio and ranks #19 among its holdings.

1,386 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Evelyn Partners Investment Management (Europe) held 21,991 shares of AstraZeneca worth $4.27M as of Q1 2026.
AstraZeneca was a new Evelyn Partners Investment Management (Europe) position in Q1 2026.
AstraZeneca made up 1.47% of Evelyn Partners Investment Management (Europe)'s portfolio in Q1 2026, its #19 holding.
1,386 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Evelyn Partners Investment Management (Europe)'s 13F filing for Q1 2026, filed 15 May 2026.